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Abstract. Presumptive treatment of malaria results in significant overuse of antimalarials. Malaria rapid diagnostic
tests (RDTs) may offer a reliable alternative for case management, but the optimal RDT strategy is uncertain. We
compared the diagnostic accuracy of histidine-rich protein 2 (HRP2)- and plasmodium lactate dehydrogenase (pLDH)-
based RDTs, using expert microscopy as the gold standard, in a longitudinal study of 918 fever episodes over an 8-month
period in a cohort of children in Kampala, Uganda. Sensitivity was 92% for HRP2 and 85% for pLDH, with differences
primarily due to better detection with HRP2 at low parasite densities. Specificity was 93% for HRP2 and 100% for
pLDH, with differences primarily due to rapid clearance of pLDH antigenemia after treatment of a previous malaria
episode. RDTs may provide an effective strategy for improving rational delivery of antimalarial therapy; in Kampala,
either test could dramatically decrease inappropriate presumptive treatments.
INTRODUCTION
Diagnostic capabilities are limited in Africa, and in most
cases fevers are treated presumptively as malaria without
laboratory-confirmed diagnosis. In many settings, presump-
tive treatment of all fevers as malaria results in extensive
overuse of antimalarials and delays the diagnosis of other
causes of fever.1–4 With older antimalarial drugs, which were
inexpensive, safe, and widely available, the potential benefits
of early treatment of all fevers supported presumptive anti-
malarial therapy. However, in the era of increasing drug re-
sistance, new combination therapies are being deployed that
are much more expensive and have less established safety
records.5,6 In this setting, improved ability to diagnose ma-
laria may prevent many unnecessary antimalarial treatments
and should also allow prompt attention to other causes of
fever when malaria is ruled out. Light microscopy, for de-
cades the gold standard for malaria diagnosis, remains un-
available to most patients in Africa.7,8 Malaria rapid diagnos-
tic tests (RDTs), newer diagnostic modalities that identify
circulating antigens of malaria parasites, may offer a reliable
alternative for case management.
The most studied malaria RDTs offer simple identification
of two parasite antigens: histidine-rich protein 2 (HRP2) and
plasmodium lactate dehydrogenase (pLDH). HRP2 was the
first antigen targeted by an RDT,9 has been available in vari-
ous commercial formats for several years, has shown good
sensitivity in a variety of field settings, and is increasingly
advocated as a diagnostic test where reliable microscopy is
not available. A potential problem for HRP2-based assays is
persistence of detectable circulating antigen for up to several
weeks after parasites have been eradicated.10–12 Persistent
HRP2 antigenemia has not correlated with treatment failure,
suggesting that this finding is not representative of persistent
infection.10,12 Persistent antigenemia thus may limit the use-
fulness of HRP2-based assays in areas of intense malaria
transmission, where positive tests may commonly be due to
prior infections that are no longer clinically relevant. pLDH-
based RDTs appear to be slightly less sensitive than those
detecting HRP2, but the antigen is rapidly cleared from the
bloodstream, becoming undetectable at about the same time
blood smears become negative after antimalarial therapy.13–15
Thus, if sensitivity is adequate, the increased specificity of
pLDH-based assays for acute malaria suggests that they may
be better-suited for high-transmission areas, such as much of
sub-Saharan Africa. With increasing advocacy for the imple-
mentation of RDTs, it is critical that optimal diagnostic strat-
egies are identified. The true impact of the varied sensitivity
and specificity of different tests is best compared with long-
term follow-up to consider the impacts of prior infections and
persistent antigenemia on test results. For this reason, we
compared the diagnostic accuracy of HRP2- and pLDH-
based RDTs, using expert microscopy as the gold standard, in
a longitudinal cohort of children in Kampala, Uganda.
METHODS
Study population and longitudinal drug-efficacy trial. We
evaluated two RDTs in a cohort of 601 children enrolled in an
on-going longitudinal antimalarial treatment efficacy trial in
Kampala. The trial began in November 2004, and is based at
Mulago Hospital, Uganda’s main public hospital. Participat-
ing children are residents of Mulago III parish, located within
2 km of Mulago Hospital. Households were randomly se-
lected for enrollment into the trial after a census of the par-
ish.16 Children in the study cohort receive all their medical
care free of charge at our study clinic. Participants are en-
couraged to come to the clinic promptly for any illness and to
avoid any medications not administered by study clinic staff.
Participants are seen at least monthly, either at the study
clinic for evaluation of illness or for routine follow-up visits,
or during home visits. Each time a participant presents to the
study clinic with fever (documented tympanic temperature
 38°C or history of fever within the previous 24 hours), a
fingerprick blood sample is obtained for thick and thin smears
and storage on filter paper. If the blood smear is positive, the
child is treated with antimalarials and followed for 28 days; if
the smear is negative, the child does not receive antimalarials
and is treated according to standard clinical algorithms and
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the study physician’s judgment. Parents/guardians gave in-
formed consent for all study procedures, and the study was
approved by the Uganda National Council of Science & Tech-
nology and by the institutional review boards of Makerere
University and the University of California, San Francisco.
RDT study methods. At the time of the RDT evaluation,
children in the cohort ranged in age from 1.5 to 11.5 years.
From October 2005 to May 2006, each time a blood smear was
done to evaluate fever in a study participant, except when the
fever occurred within 3 days of a confirmed episode of ma-
laria, a fingerprick blood sample was obtained for the two
RDTs in addition to thick and thin smears and storage on
filter paper (Figure 1). If a participant presented with re-
peated episodes of fever after diagnosis of a non-malarial
illness, the RDT was repeated at the study physician’s discre-
tion. Clinical management was guided by microscopy results;
RDT results did not influence patient care.
Thick and thin smears were stained with 2% Giemsa for 30
minutes and read by experienced laboratory technologists.
Parasite densities were calculated from thick smears by count-
ing the number of asexual parasites per 200 leukocytes (or per
500 leukocytes, if the count was < 10 asexual parasites/200
leukocytes), assuming a leukocyte count of 8,000/L. Smears
were considered negative if the examination of 100 high-
power fields did not reveal asexual parasites. Gametocytemia
was determined from thick smears and parasite species from
thin smears. All smears were read a second time by study
laboratory staff to confirm results, and discrepant readings
were resolved by a third reader. If the first and second readers
both reported a positive smear, but the second density report
differed from the first by  2000/L, the final density re-
corded was that of the third reader.
RDTs were selected for evaluation on the basis of ease of
use (relatively few preparation steps and clear distinction be-
tween positive and negative results), safety (minimal expo-
sure to blood during test preparation), completeness of pack-
aging and labeling, appropriate packaging for transport and
storage in tropical environments (each test individually
wrapped in foil with plastic liner and desiccant), low market
price, and reliability of supply. The RDTs studied were
Paracheck (detection of HRP2, Orchid Biomedical Systems,
Goa, India) and Parabank (detection of pLDH, Zephyr Bio-
medicals, Goa, India). RDTs were obtained directly from the
manufacturers and stored in their original packaging at room
temperature in the study clinic. Temperature and humidity of
the storage area were monitored, but not controlled. Over the
course of the study period, the temperature in the storage
area ranged from 19 to 29°C, with a mean low of 24°C and a
mean high of 27°C. The relative humidity ranged from 31% to
82%, with a mean low of 53% and a mean high of 69%. Prior
to the beginning of the study, positive and negative control
blood samples were obtained, and stored at −80°C for quality-
control testing of RDTs throughout the study. Each batch of
RDTs underwent quality-control testing when opened and at
8- to 12-week intervals thereafter. The two positive control
samples had densities 84/L and 5000/L, respectively. All
FIGURE 1. Trial profile showing clinic visits, blood smear results, rapid diagnostic tests (RDTs) performed (italics), and malaria episodes
(bold). At the beginning of the RDT evaluation, 565 children were enrolled in the study cohort; 524 remained enrolled at the end of the evaluation.
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HRP2 RDTs tested with quality-control samples were accu-
rate; all pLDH RDTs tested were accurate for the negative
and 5000/L samples, but only 2 of 8 were accurate for the
84/L sample.
RDTs were prepared and read by study physicians and then
read by laboratory technicians. All readers were trained to
perform the tests according to manufacturers’ instructions.
Study physicians interpreted and recorded RDT results after
15 minutes, at which time they were unaware of blood smear
results. They were advised that if the background of the RDT
test window remained pink (bloody) at the end of 15 minutes,
they should allow the background to clear before reading the
RDT. RDTs were then carried to the adjacent study labora-
tory, where they were re-read by laboratory technicians who
were unaware of both the physician’s interpretation and the
patient’s microscopy result. Readers recorded RDT results as
either positive or negative; they were trained to consider faint
test lines as positive.
Molecular methods. PCR was performed to identify para-
site species in samples positive by microscopy but negative by
RDT, as well as to detect subpatent infections in samples
negative by microscopy but positive by RDT, and in a random
sample of microscopy-negative and RDT-negative samples.
DNA was extracted from filter paper samples using Chelex
resin17 and stored at −20°C until use. To detect Plasmodium
falciparum, the block-3 region of merozoite surface protein-2
(msp-2) was amplified by nested PCR with primers corre-
sponding to conserved sequences flanking this region18 fol-
lowed by primers to amplify the IC3D7 and FC27 allelic fami-
lies, using conditions described previously.19 In addition, to
detect P. falciparum, P. vivax, P. malariae, and P. ovale, ge-
nus-specific followed by nested species-specific PCR of 18S
small subunit ribosomal RNA20 (ssu rRNA) for the four spe-
cies (Malaria Research and Reference Reagent Resource
Center, Manassas, VA) was performed, using oligonucleotide
primers and conditions as described previously.21 PCR prod-
ucts were analyzed by electrophoresis using 2% agarose gels.
Statistical methods. Data were entered using Epi-Info ver-
sion 6.04 (Centers for Disease Control and Prevention, At-
lanta, GA) and analyzed with Stata version 8.0 (Stata Corpo-
ration, College Station, TX). Sensitivity, specificity, and posi-
tive and negative predictive values were calculated by
comparing the proportion of positive and negative results for
each RDT with expert microscopy. Categorical variables
were compared using 2 or Fisher’s exact test. A P value of
< 0.05 was considered statistically significant.
RESULTS
Overall RDT accuracy. We evaluated 918 episodes of fe-
ver over an 8-month interval in children from our cohort in
Kampala (Figure 1). Over the 8-month period, 868 fevers
were new fevers in a previously well child, 21 occurred 4–14
days after a diagnosis of malaria, and 44 occurred during
follow-up of a non-malarial illness. RDTs were not performed
in 15 episodes, in 9 at the discretion of the physician during
follow-up of a non-malarial febrile illness, and in 6 because of
protocol errors. Light microscopy identified positive malaria
smears in 289 episodes (31%). Blood smear results served as
the gold standard for comparison with RDT results. As RDT
results are dependent on reader accuracy, we compared read-
ings by two groups of clinic personnel: study physicians and
laboratory technicians. In both cases, the sensitivity (> 92%)
and negative predictive value (> 96%) were higher for the
HRP2 assay, and specificity (> 99%) and positive predictive
value (> 99%) were higher for the pLDH assay (Figure 2).
First readers interpreted RDT results an average of 15 min-
utes after preparation, and second readers interpreted results
an average of 7 minutes later. First and second test readings
agreed in 98% of readings; they disagreed for 16 HRP2 tests
and 13 pLDH tests. For 14/16 (88%) discordant HRP2 read-
ings and 10/13 (77%) discordant pLDH readings, only second
readings were positive.
Evaluation of false-negative results. Possible reasons for
false-negative RDT results include low parasite density, non-
falciparum parasite species, and interpreting the RDT before
the test line has fully developed. HRP2 is produced only by P.
falciparum parasites, while the pLDH assay evaluated here
detects antigen from all human malaria parasites, although
some reports suggest pLDH may be less sensitive for non-
falciparum species.22,23
Of the 22 false-negative HRP2 results (based on first read-
ing), 15 (68%) occurred in non-falciparum infections (Figure
3). Of the remaining 7 false negatives, 5 were interpreted as
positive by the second reader. The 2 remaining false negatives
occurred in a P. falciparum mono-infection with parasite den-
sity 48/L, and a P. falciparum and P. vivax mixed infection
with density 680/L. Considering only P. falciparum infec-
tions, the sensitivity of the HRP2 assay at the second reading
was 99% (272/274).
Of the 43 false-negative pLDH results, 12 (28%) occurred
in non-falciparum infections; the remaining 31 were all P.
falciparum mono-infections. Of these 31 false negatives, 9
were interpreted as positive by the second reader. For the
remaining 22 false negatives, the geometric mean parasite
density was 352/L (range 16 to 26,080/L). Considering only
P. falciparum infections, the overall sensitivity of the pLDH
assay at the second reading was 91% (250/274). The sensitiv-
ity for P. falciparum infections decreased from 98% (217/222)
to 88% (28/32) to 25% (5/20) for parasite densities > 5000/L,
between 1000 and 5000/L, and  1000/L, respectively (P <
0.0001).
Evaluation of false-positive results. Possible reasons for
false-positive RDT results include persistent antigenemia af-
ter antimalarial treatment, detection of gametocytes when
asexual forms are not present, RDT detection of low-density
microscopy-negative infections, or presence of antigenemia
early in infection before parasites are detected by microscopy.
Of the 42 false-positive HRP2 results, 12 (29%) occurred
within 14 days of a prior diagnosis of malaria, 26 (62%) within
28 days, and 32 (76%) within 42 days. In contrast, negative
HRP2 results occurred as early as 7 days after initial diagnosis
of a previous episode of malaria.
Gametocytes were detected by microscopy in only 12 of the
918 cases (1.3%). No HRP2 result was positive in a case
where the smear showed gametocytes but not asexual para-
sites.
PCR was conducted to assess whether false-positive RDT
results may have been associated with subpatent parasitemia.
Of 40 evaluable false-positive HRP2 results, PCR was posi-
tive for P. falciparum in 8 (20%), compared with PCR posi-
tivity in 5/66 (8%) of control HRP2- and microscopy-negative
samples (P 0.07). Four of the 8 smear-negative, RDT- and
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PCR-positive samples were obtained within 28 days of a prior
episode of malaria.
Negative HRP2 results were recorded up to 3 days prior to
an episode of malaria. Only one patient developed malaria
within a week after a false-positive HRP2 result. The sample
from the initial evaluation showed no asexual parasites or
gametocytes but was positive for P. falciparum by PCR. The
patient returned with persistent fever 5 days after initial
evaluation, at which time the blood smear was positive, with
parasite density 52,840/L.
Only one pLDH test result was false-positive, in a patient
who had no documented previous episode of malaria over 469
days of follow-up, and no malaria during the subsequent 2
months of study follow-up. No gametocytes were seen in the
smear, the sample was negative by PCR for all four malaria
species, and the second reading of the RDT was negative,
strongly suggesting that this false positive was due to an error
during the first test reading.
DISCUSSION
As compared with microscopy, both HRP2- and pLDH-
based RDTs demonstrated acceptable sensitivity and speci-
ficity for the diagnosis of malaria in Kampala. The HRP2
assay showed superior sensitivity but inferior specificity com-
pared with the pLDH assay. The longitudinal design of our
study allowed us to clarify the relative importance of con-
tributors to RDT false-negative and false-positive results. The
difference in sensitivity between the tests was due mostly to
better detection with HRP2 at low parasite densities. Non-
falciparum infections contributed to false-negative results for
both RDTs. In particular, in two-thirds of cases in which the
HRP2 test was negative although microscopy detected para-
sites, the infection was caused by non-falciparum species. The
higher specificity and positive predictive value of the pLDH
assay was due to the fact that pLDH antigenemia closely
mirrors parasitemia, while HRP2 commonly persists in the
bloodstream weeks after successful treatment of malaria.10,12
Subpatent parasitemia, as detected by PCR, pre-patent infec-
tions, and gametocytemia, did not appear to contribute im-
portantly to false-positive results for either RDT. In sum-
mary, both studied RDTs accurately identified clinically rel-
evant malaria infections but they differed importantly in
sensitivity and specificity.
In Uganda, RDTs are increasingly available in the private
FIGURE 2. Point estimates of RDT accuracy. Blood smears were read by experienced microscopists in the study laboratory. All smears were
read a second time by study laboratory staff to confirm results, and discrepant readings were resolved by a third reader. RDTs were read
sequentially by study physicians and laboratory technicians, as described in Methods.
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health care sector and are widely advocated for use in the
public sector, though clear guidelines or algorithms for their
use are lacking. In Kampala, both the HRP2 and pLDH tests
showed a high negative predictive value and appeared to offer
good reliability in ruling out malaria as the cause of a fever.
Considering the potential values of RDTs, some limitations in
both sensitivity and specificity may be acceptable. The lower
specificity of the HRP2-based test, due to persistent antigen-
emia after recent infections, may lead to some inappropriate
treatments, but many fewer than if all episodes of fever were
treated as malaria. However, the lower specificity of HRP2
assays may be more problematic, with many more unneces-
sary malaria treatments, in regions with higher transmission
intensity than Kampala. The lower sensitivity of the pLDH-
based assay might also be a concern, but in Kampala, missed
episodes were primarily of relatively low parasitemia, sug-
gesting that, in immune populations, mostly mild or asymp-
tomatic infections will be missed. Indeed, especially if tech-
nological innovations can improve the sensitivity of pLDH-
based tests, they may well offer the optimal balance of
sensitivity and specificity for the diagnosis of malaria in Af-
rica.
To our knowledge, this study offers the first comparison of
RDTs in a longitudinal format, allowing assessment of the
importance of previous and future malaria infections in RDT
accuracy. A number of other RDT evaluations have been
conducted, though results have varied widely, likely due at
least in part to different methodologies and locations. Two
previous RDT studies in western Uganda compared HRP2-
based tests with expert microscopy. One evaluation, using an
older HRP2 assay, found a sensitivity of 99.6% for parasit-
emia > 500/L and specificity of 92.7% in patients with fe-
ver.24 The other study, using the same HRP2 test as in our
evaluation, found a sensitivity of 97% and specificity of 88%
for P. falciparum infections.25 These estimates are similar to
those for the HRP2-based test in our current evaluation. Our
results also confirm the superior specificity of pLDH seen in
a study in Tanzania,26 although sensitivity of both tests was
somewhat lower in our study.
Our results are not immediately applicable to fever case
management across Africa. We obtained RDTs directly from
manufacturers, and we used and stored kits as recommended
by manufacturers; adherence to these guidelines may be chal-
lenging in rural settings, and test quality is likely to deterio-
rate if kits are less well maintained.27 Our evaluation was
performed in an area with relatively low malaria transmission.
Because of the location and design of our study, our patients
likely presented to the clinic earlier in the course of malaria
than in non-research settings. Our staff was carefully trained
in use of the two RDTs before initiation of our study; test
accuracy may be lower in field settings, although a number of
reports indicate that village health workers with minimal
training are able to satisfactorily prepare and interpret
RDTs.28,29 Considering these limitations, how should the re-
sults of this evaluation influence malaria treatment policy?
For Kampala, our results suggest that, in settings without ac-
cess to microscopy, use of either HRP2- or pLDH-based
RDTs could dramatically lower the use of inappropriate an-
timalarial therapy without missing many episodes of clinical
malaria. However, it will be necessary to perform similar
analyses in areas with different epidemiology to determine
the predictive values of different RDTs in various settings. In
addition, the issue of cost and cost-effectiveness of RDTs,
compared with presumptive treatment and with diagnosis with
microscopy, must be considered. In the era of artemisinin
combination therapies, using RDTs to target treatment to
confirmed cases of malaria may help to maximize the impact
of these valuable resources.
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